{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T12:33:07Z","timestamp":1792153987779,"version":"4.4.0"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2019,9,23]],"date-time":"2019-09-23T00:00:00Z","timestamp":1569196800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,9,23]],"date-time":"2019-09-23T00:00:00Z","timestamp":1569196800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100008363","name":"Kr\u00e6ftens Bek\u00e6mpelse","doi-asserted-by":"publisher","award":["R150-A10023"],"award-info":[{"award-number":["R150-A10023"]}],"id":[{"id":"10.13039\/100008363","id-type":"DOI","asserted-by":"publisher"}]},{"name":"The Faculty of Health Sciences, The University of Southern Denmnark"},{"name":"Amgen A\/S"},{"name":"Celgene A\/S"},{"name":"Takeda A\/S"},{"name":"Janssen A\/S"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Qual Life Res"],"published-print":{"date-parts":[[2020,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n<jats:sec>\n<jats:title>Purpose<\/jats:title>\n<jats:p>The quality of patient-reported outcome (PRO) data can be compromised by non-response (NR) to scheduled questionnaires, particularly if reasons for NR are related to health problems, which may lead to unintended bias. The aim was to investigate whether electronic reminders and real-time monitoring improve PRO completion rate.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>The population-based study \u201cQuality of life in Danish multiple myeloma patients\u201d is a longitudinal, multicentre study with consecutive inclusion of treatment-demanding newly diagnosed or relapsed patients with multiple myeloma. Education of study nurses in the avoidance of NR, electronic reminders, 7-day response windows and real-time monitoring of NR were integrated in the study. Patients complete PRO assessments at study entry and at 12 follow-up time points using electronic or paper questionnaires. The effect of the electronic reminders and real-time monitoring were investigated by comparison of proportions of completed questionnaires before and after each intervention.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>The first 271 included patients were analysed; of those, 249 (85%) chose electronic questionnaires. Eighty-four percent of the 1441 scheduled PRO assessments were completed within the 7-day response window and 11% after real-time monitoring, achieving a final PRO completion rate of 95%. A significant higher proportion of uncompleted questionnaires were completed after the patients had received the electronic reminder and after real-time monitoring.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>Electronic reminders and real-time monitoring contributed to a very high completion rate in the study. To increase the quality of PRO data, we propose integrating these strategies in PRO studies, however highlighting that an increase in staff resources is required for implementation.<\/jats:p>\n<\/jats:sec>","DOI":"10.1007\/s11136-019-02304-8","type":"journal-article","created":{"date-parts":[[2019,9,23]],"date-time":"2019-09-23T14:03:26Z","timestamp":1569247406000},"page":"335-346","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["Strategies to improve patient-reported outcome completion rates in longitudinal studies"],"prefix":"10.1007","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2083-3870","authenticated-orcid":false,"given":"Lene Kongsgaard","family":"Nielsen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madeleine","family":"King","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00f6ren","family":"M\u00f6ller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Jarden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christen Lykkegaard","family":"Andersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Frederiksen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Gregersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja","family":"Klostergaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morten Saaby","family":"Steffensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per Tr\u00f8llund","family":"Pedersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maja","family":"Hinge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikael","family":"Frederiksen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo Amdi","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carsten","family":"Helleberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne K\u00e6rsgaard","family":"Mylin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels","family":"Abildgaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,9,23]]},"reference":[{"issue":"6","key":"2304_CR1","doi-asserted-by":"publisher","first-page":"2962","DOI":"10.1182\/blood-2007-10-078022","volume":"111","author":"RA Kyle","year":"2008","unstructured":"Kyle, R. A., & Rajkumar, S. V. (2008). Multiple myeloma. Blood,111(6), 2962\u20132972. \nhttps:\/\/doi.org\/10.1182\/blood-2007-10-078022\n\n.","journal-title":"Blood"},{"issue":"12","key":"2304_CR2","doi-asserted-by":"publisher","first-page":"e538","DOI":"10.1016\/s1470-2045(14)70442-5","volume":"15","author":"SV Rajkumar","year":"2014","unstructured":"Rajkumar, S. V., Dimopoulos, M. A., Palumbo, A., Blade, J., Merlini, G., Mateos, M. V., et al. (2014). International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. The lancet Oncology,15(12), e538\u2013e548. \nhttps:\/\/doi.org\/10.1016\/s1470-2045(14)70442-5\n\n.","journal-title":"The lancet Oncology"},{"issue":"5","key":"2304_CR3","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1182\/blood-2007-10-116129","volume":"111","author":"SK Kumar","year":"2008","unstructured":"Kumar, S. K., Rajkumar, S. V., Dispenzieri, A., Lacy, M. Q., Hayman, S. R., Buadi, F. K., et al. (2008). Improved survival in multiple myeloma and the impact of novel therapies. Blood,111(5), 2516\u20132520.","journal-title":"Blood"},{"issue":"5","key":"2304_CR4","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1038\/leu.2013.313","volume":"28","author":"SK Kumar","year":"2014","unstructured":"Kumar, S. K., Dispenzieri, A., Lacy, M. Q., Gertz, M. A., Buadi, F. K., Pandey, S., et al. (2014). Continued improvement in survival in multiple myeloma: Changes in early mortality and outcomes in older patients. Leukemia,28(5), 1122\u20131128. \nhttps:\/\/doi.org\/10.1038\/leu.2013.313\n\n.","journal-title":"Leukemia"},{"issue":"2","key":"2304_CR5","doi-asserted-by":"publisher","first-page":"163","DOI":"10.3324\/haematol.2008.002766","volume":"94","author":"J Blade","year":"2009","unstructured":"Blade, J., & Rosinol, L. (2009). Changing paradigms in the treatment of multiple myeloma. Haematologica,94(2), 163\u2013166. \nhttps:\/\/doi.org\/10.3324\/haematol.2008.002766\n\n.","journal-title":"Haematologica"},{"issue":"2","key":"2304_CR6","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1111\/j.1365-2141.2004.04879.x","volume":"125","author":"A Waage","year":"2004","unstructured":"Waage, A., Gimsing, P., Juliusson, G., Turesson, I., Gulbrandsen, N., Eriksson, T., et al. (2004). Early response predicts thalidomide efficiency in patients with advanced multiple myeloma. British Journal of Haematology,125(2), 149\u2013155. \nhttps:\/\/doi.org\/10.1111\/j.1365-2141.2004.04879.x\n\n.","journal-title":"British Journal of Haematology"},{"issue":"11","key":"2304_CR7","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1016\/s1470-2045(13)70380-2","volume":"14","author":"JS Miguel","year":"2013","unstructured":"Miguel, J. S., Weisel, K., Moreau, P., Lacy, M., Song, K., Delforge, M., et al. (2013). Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): A randomised, open-label, phase 3 trial. The lancet Oncology,14(11), 1055\u20131066. \nhttps:\/\/doi.org\/10.1016\/s1470-2045(13)70380-2\n\n.","journal-title":"The lancet Oncology"},{"issue":"21","key":"2304_CR8","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1056\/NEJMoa070596","volume":"357","author":"DM Weber","year":"2007","unstructured":"Weber, D. M., Chen, C., Niesvizky, R., Wang, M., Belch, A., Stadtmauer, E. A., et al. (2007). Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. New England Journal of Medicine,357(21), 2133\u20132142. \nhttps:\/\/doi.org\/10.1056\/NEJMoa070596\n\n.","journal-title":"New England Journal of Medicine"},{"issue":"17","key":"2304_CR9","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1056\/NEJMoa1516282","volume":"374","author":"P Moreau","year":"2016","unstructured":"Moreau, P., Masszi, T., Grzasko, N., Bahlis, N. J., Hansson, M., Pour, L., et al. (2016). Oral Ixazomib, lenalidomide, and dexamethasone for multiple myeloma. The New England Journal of Medicine,374(17), 1621\u20131634. \nhttps:\/\/doi.org\/10.1056\/NEJMoa1516282\n\n.","journal-title":"The New England Journal of Medicine"},{"issue":"2","key":"2304_CR10","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1056\/nejmoa1411321","volume":"372","author":"AK Stewart","year":"2015","unstructured":"Stewart, A. K., Rajkumar, S. V., Dimopoulos, M. A., Masszi, T., Spicka, I., Oriol, A., et al. (2015). Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. The New England Journal of Medicine,372(2), 142\u2013152. \nhttps:\/\/doi.org\/10.1056\/nejmoa1411321\n\n.","journal-title":"The New England Journal of Medicine"},{"issue":"26","key":"2304_CR11","doi-asserted-by":"publisher","first-page":"2609","DOI":"10.1056\/NEJMoa030288","volume":"348","author":"PG Richardson","year":"2003","unstructured":"Richardson, P. G., Barlogie, B., Berenson, J., Singhal, S., Jagannath, S., Irwin, D., et al. (2003). A phase 2 study of Bortezomib in relapsed, refractory myeloma. New England Journal of Medicine,348(26), 2609\u20132617. \nhttps:\/\/doi.org\/10.1056\/NEJMoa030288\n\n.","journal-title":"New England Journal of Medicine"},{"issue":"8","key":"2304_CR12","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1056\/NEJMoa1606038","volume":"375","author":"A Palumbo","year":"2016","unstructured":"Palumbo, A., Chanan-Khan, A., Weisel, K., Nooka, A. K., Masszi, T., Beksac, M., et al. (2016). Daratumumab, bortezomib, and dexamethasone for multiple myeloma. New England Journal of Medicine,375(8), 754\u2013766. \nhttps:\/\/doi.org\/10.1056\/NEJMoa1606038\n\n.","journal-title":"New England Journal of Medicine"},{"issue":"7","key":"2304_CR13","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1056\/NEJMoa1505654","volume":"373","author":"S Lonial","year":"2015","unstructured":"Lonial, S., Dimopoulos, M., Palumbo, A., White, D., Grosicki, S., Spicka, I., et al. (2015). Elotuzumab therapy for relapsed or refractory multiple myeloma. New England Journal of Medicine,373(7), 621\u2013631. \nhttps:\/\/doi.org\/10.1056\/NEJMoa1505654\n\n.","journal-title":"New England Journal of Medicine"},{"issue":"3","key":"2304_CR14","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/leu.2013.350","volume":"28","author":"EM Ocio","year":"2014","unstructured":"Ocio, E. M., Richardson, P. G., Rajkumar, S. V., Palumbo, A., Mateos, M. V., Orlowski, R., et al. (2014). New drugs and novel mechanisms of action in multiple myeloma in 2013: A report from the International Myeloma Working Group (IMWG). Leukemia,28(3), 525\u2013542. \nhttps:\/\/doi.org\/10.1038\/leu.2013.350\n\n.","journal-title":"Leukemia"},{"issue":"5","key":"2304_CR15","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/j.jpainsymman.2012.11.003","volume":"46","author":"E Boland","year":"2013","unstructured":"Boland, E., Eiser, C., Ezaydi, Y., Greenfield, D. M., Ahmedzai, S. H., & Snowden, J. A. (2013). Living with advanced but stable multiple myeloma: A study of the symptom burden and cumulative effects of disease and intensive (hematopoietic stem cell transplant-based) treatment on health-related quality of life. Journal of Pain and Symptom Management,46(5), 671\u2013680. \nhttps:\/\/doi.org\/10.1016\/j.jpainsymman.2012.11.003\n\n.","journal-title":"Journal of Pain and Symptom Management"},{"issue":"4","key":"2304_CR16","doi-asserted-by":"publisher","first-page":"E73","DOI":"10.1002\/ajh.23932","volume":"90","author":"MO Holmstrom","year":"2015","unstructured":"Holmstrom, M. O., Gimsing, P., Abildgaard, N., Andersen, N. F., Helleberg, C., Clausen, N. A., et al. (2015). Causes of early death in multiple myeloma patients who are ineligible for high-dose therapy with hematopoietic stem cell support: A study based on the nationwide Danish Myeloma Database. American Journal of Hematology,90(4), E73\u2013E74. \nhttps:\/\/doi.org\/10.1002\/ajh.23932\n\n.","journal-title":"American Journal of Hematology"},{"issue":"SUPPL. 2","key":"2304_CR17","doi-asserted-by":"publisher","first-page":"S24","DOI":"10.1016\/S0305-7372%2810%2970009-8","volume":"36","author":"MV Mateos","year":"2010","unstructured":"Mateos, M. V. (2010). Management of treatment-related adverse events in patients with multiple myeloma. Cancer Treatment Reviews,36(SUPPL. 2), S24\u2013S32. \nhttps:\/\/doi.org\/10.1016\/S0305-7372%2810%2970009-8\n\n.","journal-title":"Cancer Treatment Reviews"},{"issue":"4","key":"2304_CR18","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1038\/leu.2011.346","volume":"26","author":"PG Richardson","year":"2012","unstructured":"Richardson, P. G., Delforge, M., Beksac, M., Wen, P., Jongen, J. L., Sezer, O., et al. (2012). Management of treatment-emergent peripheral neuropathy in multiple myeloma. Leukemia,26(4), 595\u2013608. \nhttps:\/\/doi.org\/10.1038\/leu.2011.346\n\n.","journal-title":"Leukemia"},{"issue":"5","key":"2304_CR19","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1111\/ejh.12790","volume":"97","author":"C Ramsenthaler","year":"2016","unstructured":"Ramsenthaler, C., Kane, P., Gao, W., Siegert, R. J., Edmonds, P. M., Schey, S. A., et al. (2016). Prevalence of symptoms in patients with multiple myeloma: A systematic review and meta-analysis. European Journal of Haematology,97(5), 416\u2013429. \nhttps:\/\/doi.org\/10.1111\/ejh.12790\n\n.","journal-title":"European Journal of Haematology"},{"issue":"2","key":"2304_CR20","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1007\/s00520-013-1991-4","volume":"22","author":"K Jordan","year":"2014","unstructured":"Jordan, K., Proskorovsky, I., Lewis, P., Ishak, J., Payne, K., Lordan, N., et al. (2014). Effect of general symptom level, specific adverse events, treatment patterns, and patient characteristics on health-related quality of life in patients with multiple myeloma: Results of a European, multicenter cohort study. Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer,22(2), 417\u2013426. \nhttps:\/\/doi.org\/10.1007\/s00520-013-1991-4\n\n.","journal-title":"Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer"},{"issue":"2","key":"2304_CR21","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1111\/j.1600-0609.2009.01250.x","volume":"83","author":"AT Johnsen","year":"2009","unstructured":"Johnsen, A. T., Tholstrup, D., Petersen, M. A., Pedersen, L., & Groenvold, M. (2009). Health related quality of life in a nationally representative sample of haematological patients. European Journal of Haematology,83(2), 139\u2013148. \nhttps:\/\/doi.org\/10.1111\/j.1600-0609.2009.01250.x\n\n.","journal-title":"European Journal of Haematology"},{"issue":"2","key":"2304_CR22","first-page":"117","volume":"66","author":"D Priscilla","year":"2011","unstructured":"Priscilla, D., Hamidin, A., Azhar, M. Z., Noorjan, K. O. N., Salmiah, M. S., & Bahariah, K. (2011). Quality of life among patients with hematological cancer in a Malaysian hospital. Medical Journal of Malaysia,66(2), 117.","journal-title":"Medical Journal of Malaysia"},{"issue":"1","key":"2304_CR23","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/ejh.12882","volume":"99","author":"LK Nielsen","year":"2017","unstructured":"Nielsen, L. K., Jarden, M., Andersen, C. L., Frederiksen, H., & Abildgaard, N. (2017). A systematic review of health-related quality of life in longitudinal studies of myeloma patients. European Journal of Haematology,99(1), 3\u201317. \nhttps:\/\/doi.org\/10.1111\/ejh.12882\n\n.","journal-title":"European Journal of Haematology"},{"issue":"5","key":"2304_CR24","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","volume":"85","author":"NK Aaronson","year":"1993","unstructured":"Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., et al. (1993). The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. Journal of the National Cancer Institute,85(5), 365\u2013376.","journal-title":"Journal of the National Cancer Institute"},{"issue":"2","key":"2304_CR25","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1001\/jama.2017.7156","volume":"318","author":"E Basch","year":"2017","unstructured":"Basch, E., Deal, A. M., Dueck, A. C., Scher, H. I., Kris, M. G., Hudis, C., et al. (2017). Overall survival results of a trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment. JAMA,318(2), 197\u2013198. \nhttps:\/\/doi.org\/10.1001\/jama.2017.7156\n\n.","journal-title":"JAMA"},{"issue":"2","key":"2304_CR26","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1093\/annonc\/mdy488","volume":"30","author":"RD Nipp","year":"2019","unstructured":"Nipp, R. D., El-Jawahri, A., Ruddy, M., Fuh, C., Temel, B., D\u2019Arpino, S. M., et al. (2019). Pilot randomized trial of an electronic symptom monitoring intervention for hospitalized patients with cancer. Annals of Oncology,30(2), 274\u2013280. \nhttps:\/\/doi.org\/10.1093\/annonc\/mdy488\n\n.","journal-title":"Annals of Oncology"},{"issue":"5","key":"2304_CR27","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1177\/0962280213476378","volume":"23","author":"ML Bell","year":"2014","unstructured":"Bell, M. L., & Fairclough, D. L. (2014). Practical and statistical issues in missing data for longitudinal patient-reported outcomes. Statistical Methods in Medical Research,23(5), 440\u2013459. \nhttps:\/\/doi.org\/10.1177\/0962280213476378\n\n.","journal-title":"Statistical Methods in Medical Research"},{"key":"2304_CR28","doi-asserted-by":"publisher","DOI":"10.1201\/9781420061185","volume-title":"Design and analysis of quality of life studies in clinical trials","author":"DL Fairclough","year":"2010","unstructured":"Fairclough, D. L. (2010). Design and analysis of quality of life studies in clinical trials (2nd ed.). Boca Raton: Chapman & Hall\/CRC.","edition":"2"},{"issue":"6","key":"2304_CR29","doi-asserted-by":"publisher","first-page":"e010938","DOI":"10.1136\/bmjopen-2015-010938","volume":"6","author":"R Mercieca-Bebber","year":"2016","unstructured":"Mercieca-Bebber, R., Palmer, M. J., Brundage, M., Calvert, M., Stockler, M. R., & King, M. T. (2016). Design, implementation and reporting strategies to reduce the instance and impact of missing patient-reported outcome (PRO) data: A systematic review. The BMJ Open,6(6), e010938. \nhttps:\/\/doi.org\/10.1136\/bmjopen-2015-010938\n\n.","journal-title":"The BMJ Open"},{"issue":"5","key":"2304_CR30","doi-asserted-by":"publisher","first-page":"e381","DOI":"10.1111\/ajco.12580","volume":"13","author":"RL Mercieca-Bebber","year":"2017","unstructured":"Mercieca-Bebber, R. L., Price, M. A., Bell, M. L., King, M. T., Webb, P. M., & Butow, P. N. (2017). Ovarian cancer study dropouts had worse health-related quality of life and psychosocial symptoms at baseline and over time. Asia-Pacific Journal of Clinical Oncology,13(5), e381\u2013e388. \nhttps:\/\/doi.org\/10.1111\/ajco.12580\n\n.","journal-title":"Asia-Pacific Journal of Clinical Oncology"},{"key":"2304_CR31","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.conctc.2017.11.009","volume":"9","author":"R Mercieca-Bebber","year":"2018","unstructured":"Mercieca-Bebber, R., Calvert, M., Kyte, D., Stockler, M., & King, M. T. (2018). The administration of patient-reported outcome questionnaires in cancer trials: Interviews with trial coordinators regarding their roles, experiences, challenges and training. Contemporary Clinical Trials Communications,9, 23\u201332.","journal-title":"Contemporary Clinical Trials Communications"},{"issue":"1 Supplement 1","key":"2304_CR32","first-page":"102","volume":"26","author":"R Mercieca-Bebber","year":"2017","unstructured":"Mercieca-Bebber, R., Kyte, D. G., Calvert, M. J., Stockler, M., & King, M. T. (2017). Challenges and training needs of study coordinators responsible for administration of patient-reported outcome questionnaires in cancer trials [Conference Abstract]. Quality of Life Research,26(1 Supplement 1), 102.","journal-title":"Quality of Life Research"},{"issue":"5\u20137","key":"2304_CR33","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1002\/(SICI)1097-0258(19980315\/15)17:5\/7<781::AID-SIM821>3.0.CO;2-O","volume":"17","author":"DL Fairclough","year":"1998","unstructured":"Fairclough, D. L., Peterson, H. F., Cella, D., & Bonomi, P. (1998). Comparison of several model-based methods for analysing incomplete quality of life data in cancer clinical trials. Statistics in Medicine,17(5\u20137), 781\u2013796.","journal-title":"Statistics in Medicine"},{"issue":"5\u20137","key":"2304_CR34","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1002\/(SICI)1097-0258(19980315\/15)17:5\/7<517::AID-SIM799>3.0.CO;2-S","volume":"17","author":"J Bernhard","year":"1998","unstructured":"Bernhard, J., Cella, D. F., Coates, A. S., Fallowfield, L., Ganz, P. A., Moinpour, C. M., et al. (1998). Missing quality of life data in cancer clinical trials: Serious problems and challenges. Statistics in Medicine,17(5\u20137), 517\u2013532.","journal-title":"Statistics in Medicine"},{"issue":"11","key":"2304_CR35","doi-asserted-by":"publisher","first-page":"e510","DOI":"10.1016\/s1470-2045(16)30510-1","volume":"17","author":"A Bottomley","year":"2016","unstructured":"Bottomley, A., Pe, M., Sloan, J., Basch, E., Bonnetain, F., Calvert, M., et al. (2016). Analysing data from patient-reported outcome and quality of life endpoints for cancer clinical trials: A start in setting international standards. The lancet Oncology,17(11), e510\u2013e514. \nhttps:\/\/doi.org\/10.1016\/s1470-2045(16)30510-1\n\n.","journal-title":"The lancet Oncology"},{"issue":"5","key":"2304_CR36","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/s1470-2045(18)30141-4","volume":"19","author":"E Basch","year":"2018","unstructured":"Basch, E. (2018). Patient-reported outcomes: An essential component of oncology drug development and regulatory review. The lancet Oncology,19(5), 595\u2013597. \nhttps:\/\/doi.org\/10.1016\/s1470-2045(18)30141-4\n\n.","journal-title":"The lancet Oncology"},{"issue":"1","key":"2304_CR37","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1177\/1740774517741113","volume":"15","author":"MJ Palmer","year":"2018","unstructured":"Palmer, M. J., Mercieca-Bebber, R., King, M., Calvert, M., Richardson, H., & Brundage, M. (2018). A systematic review and development of a classification framework for factors associated with missing patient-reported outcome data. Clinical Trials,15(1), 95\u2013106. \nhttps:\/\/doi.org\/10.1177\/1740774517741113\n\n.","journal-title":"Clinical Trials"},{"issue":"34","key":"2304_CR38","doi-asserted-by":"publisher","first-page":"4249","DOI":"10.1200\/jco.2012.42.5967","volume":"30","author":"E Basch","year":"2012","unstructured":"Basch, E., Abernethy, A. P., Mullins, C. D., Reeve, B. B., Smith, M. L., Coons, S. J., et al. (2012). Recommendations for incorporating patient-reported outcomes into clinical comparative effectiveness research in adult oncology. Journal of Clinical Oncology,30(34), 4249\u20134255. \nhttps:\/\/doi.org\/10.1200\/jco.2012.42.5967\n\n.","journal-title":"Journal of Clinical Oncology"},{"issue":"5","key":"2304_CR39","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","volume":"40","author":"ME Charlson","year":"1987","unstructured":"Charlson, M. E., Pompei, P., Ales, K. L., & MacKenzie, C. R. (1987). A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. Journal of Chronic Diseases,40(5), 373\u2013383.","journal-title":"Journal of Chronic Diseases"},{"key":"2304_CR40","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1001\/jama.1963.03060120024016","volume":"185","author":"S Katz","year":"1963","unstructured":"Katz, S., Ford, A. B., Moskowitz, R. W., Jackson, B. A., & Jaffe, M. W. (1963). Studies of illness in the aged. The index of Adl: A standardized measure of biological and psychosocial function. JAMA,185, 914\u2013919.","journal-title":"JAMA"},{"issue":"3","key":"2304_CR41","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1093\/geront\/9.3_Part_1.179","volume":"9","author":"MP Lawton","year":"1969","unstructured":"Lawton, M. P., & Brody, E. M. (1969). Assessment of older people: Self-maintaining and instrumental activities of daily living. The Gerontologist,9(3), 179\u2013186.","journal-title":"The Gerontologist"},{"issue":"9","key":"2304_CR42","doi-asserted-by":"publisher","first-page":"e35","DOI":"10.1038\/bcj.2011.34","volume":"1","author":"M Kleber","year":"2011","unstructured":"Kleber, M., Ihorst, G., Terhorst, M., Koch, B., Deschler, B., Wasch, R., et al. (2011). Comorbidity as a prognostic variable in multiple myeloma: Comparative evaluation of common comorbidity scores and use of a novel MM-comorbidity score. Blood Cancer Journal,1(9), e35. \nhttps:\/\/doi.org\/10.1038\/bcj.2011.34\n\n.","journal-title":"Blood Cancer Journal"},{"issue":"13","key":"2304_CR43","doi-asserted-by":"publisher","first-page":"2068","DOI":"10.1182\/blood-2014-12-615187","volume":"125","author":"A Palumbo","year":"2015","unstructured":"Palumbo, A., Bringhen, S., Mateos, M. V., Larocca, A., Facon, T., Kumar, S. K., et al. (2015). Geriatric assessment predicts survival and toxicities in elderly myeloma patients: An International Myeloma Working Group report. Blood,125(13), 2068\u20132074. \nhttps:\/\/doi.org\/10.1182\/blood-2014-12-615187\n\n.","journal-title":"Blood"},{"issue":"9","key":"2304_CR44","doi-asserted-by":"publisher","first-page":"2002","DOI":"10.1002\/1097-0142(19840501)53:9<2002::AID-CNCR2820530933>3.0.CO;2-W","volume":"53","author":"V Mor","year":"1984","unstructured":"Mor, V., Laliberte, L., Morris, J. N., & Wiemann, M. (1984). The Karnofsky Performance Status Scale. An examination of its reliability and validity in a research setting. Cancer,53(9), 2002\u20132007.","journal-title":"Cancer"},{"key":"2304_CR45","doi-asserted-by":"publisher","first-page":"583","DOI":"10.2147\/clep.s99463","volume":"8","author":"P Gimsing","year":"2016","unstructured":"Gimsing, P., Holmstrom, M. O., Klausen, T. W., Andersen, N. F., Gregersen, H., Pedersen, R. S., et al. (2016). The Danish national multiple myeloma registry. Clinical Epidemiology,8, 583\u2013587. \nhttps:\/\/doi.org\/10.2147\/clep.s99463\n\n.","journal-title":"Clinical Epidemiology"},{"issue":"15","key":"2304_CR46","doi-asserted-by":"publisher","first-page":"3412","DOI":"10.1200\/jco.2005.04.242","volume":"23","author":"PR Greipp","year":"2005","unstructured":"Greipp, P. R., San Miguel, J., Durie, B. G., Crowley, J. J., Barlogie, B., Blade, J., et al. (2005). International staging system for multiple myeloma. Journal of Clinical Oncology,23(15), 3412\u20133420. \nhttps:\/\/doi.org\/10.1200\/jco.2005.04.242\n\n.","journal-title":"Journal of Clinical Oncology"},{"key":"2304_CR47","first-page":"263","volume":"46","author":"T Folmer Andersen","year":"1999","unstructured":"Folmer Andersen, T., Madsen, M., J\u00f8rgensen, J., Mellemkj\u00e6r, L., & Olsen, J. H. (1999). The Danish National Hospital Register: A valuable source of data for modern health sciences. Danish Medical Bulletin,46, 263\u2013268.","journal-title":"Danish Medical Bulletin"},{"issue":"11","key":"2304_CR48","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1016\/j.ejca.2007.04.022","volume":"43","author":"K Cocks","year":"2007","unstructured":"Cocks, K., Cohen, D., Wisloff, F., Sezer, O., Lee, S., Hippe, E., et al. (2007). An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-MY20) in assessing the quality of life of patients with multiple myeloma. European Journal of Cancer (Oxford, England: 1990),43(11), 1670\u20131678.","journal-title":"European Journal of Cancer (Oxford, England: 1990)"},{"issue":"8","key":"2304_CR49","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1016\/j.ejca.2005.02.012","volume":"41","author":"TJ Postma","year":"2005","unstructured":"Postma, T. J., Aaronson, N. K., Heimans, J. J., Muller, M. J., Hildebrand, J. G., Delattre, J. Y., et al. (2005). The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: The QLQ-CIPN20. European Journal of Cancer (Oxford, England: 1990),41(8), 1135\u20131139.","journal-title":"European Journal of Cancer (Oxford, England: 1990)"},{"issue":"3","key":"2304_CR50","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1097\/00005650-199603000-00003","volume":"34","author":"J Ware Jr","year":"1996","unstructured":"Ware, J., Jr., Kosinski, M., & Keller, S. D. (1996). A 12-Item Short-Form Health Survey: Construction of scales and preliminary tests of reliability and validity. Medical Care,34(3), 220\u2013233.","journal-title":"Medical Care"},{"issue":"2","key":"2304_CR51","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","volume":"42","author":"PA Harris","year":"2009","unstructured":"Harris, P. A., Taylor, R., Thielke, R., Payne, J., Gonzalez, N., & Conde, J. G. (2009). Research electronic data capture (REDCap)\u2014a metadata-driven methodology and workflow process for providing translational research informatics support. Journal of Biomedical Informatics,42(2), 377\u2013381. \nhttps:\/\/doi.org\/10.1016\/j.jbi.2008.08.010\n\n.","journal-title":"Journal of Biomedical Informatics"},{"issue":"2","key":"2304_CR52","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.ejca.2004.10.017","volume":"41","author":"D Osoba","year":"2005","unstructured":"Osoba, D., Bezjak, A., Brundage, M., Zee, B., Tu, D., & Pater, J. (2005). Analysis and interpretation of health-related quality-of-life data from clinical trials: Basic approach of The National Cancer Institute of Canada Clinical Trials Group. European Journal of Cancer,41(2), 280\u2013287. \nhttps:\/\/doi.org\/10.1016\/j.ejca.2004.10.017\n\n.","journal-title":"European Journal of Cancer"},{"key":"2304_CR53","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15759","author":"LK Nielsen","year":"2019","unstructured":"Nielsen, L. K., Abildgaard, N., Jarden, M., & Klausen, T. W. (2019). Methodological aspects of health-related quality of life measurement and analysis in patients with multiple myeloma. British Journal of Haematology. \nhttps:\/\/doi.org\/10.1111\/bjh.15759\n\n.","journal-title":"British Journal of Haematology"},{"issue":"1","key":"2304_CR54","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1385\/MO:18:1:65","volume":"18","author":"N Gulbrandsen","year":"2001","unstructured":"Gulbrandsen, N., Wisloff, F., Brinch, L., Carlson, K., Dahl, I. M., Gimsing, P., et al. (2001). Health-related quality of life in multiple myeloma patients receiving high-dose chemotherapy with autologous blood stem-cell support. Medical oncology (Northwood, London, England),18(1), 65\u201377.","journal-title":"Medical oncology (Northwood, London, England)"},{"issue":"3","key":"2304_CR55","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1046\/j.1365-2141.1996.352889.x","volume":"92","author":"F Wisloff","year":"1996","unstructured":"Wisloff, F., Eika, S., Hippe, E., Hjorth, M., Holmberg, E., Kaasa, S., et al. (1996). Measurement of health-related quality of life in multiple myeloma. Nordic Myeloma Study Group. British Journal of Haematology,92(3), 604\u2013613.","journal-title":"British Journal of Haematology"},{"issue":"14","key":"2304_CR56","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1056\/NEJMsr1203730","volume":"367","author":"RJ Little","year":"2012","unstructured":"Little, R. J., D\u2019Agostino, R., Cohen, M. L., Dickersin, K., Emerson, S. S., Farrar, J. T., et al. (2012). The prevention and treatment of missing data in clinical trials. The New England Journal of Medicine,367(14), 1355\u20131360. \nhttps:\/\/doi.org\/10.1056\/NEJMsr1203730\n\n.","journal-title":"The New England Journal of Medicine"},{"issue":"S1","key":"2304_CR57","first-page":"294","volume":"2","author":"L Nielsen","year":"2018","unstructured":"Nielsen, L., Jarden, M., Andersen, C., Frederiksen, H., Gregersen, H., Klostergaard, A., et al. (2018). Quality of life in newly diagnosed and relapsed Danish multiple myeloma patients\u2014A national longitudinal study of Danish Myeloma Study Group [Conference abstract]. HemaSphere,2(S1), 294\u2013295.","journal-title":"HemaSphere"},{"key":"2304_CR58","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1186\/1471-2407-14-758","volume":"14","author":"JM Giesinger","year":"2014","unstructured":"Giesinger, J. M., Wintner, L. M., Zabernigg, A., Gamper, E. M., Oberguggenberger, A. S., Sztankay, M. J., et al. (2014). Assessing quality of life on the day of chemotherapy administration underestimates patients\u2019 true symptom burden. BMC Cancer,14, 758. \nhttps:\/\/doi.org\/10.1186\/1471-2407-14-758\n\n.","journal-title":"BMC Cancer"},{"issue":"1","key":"2304_CR59","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1186\/s12885-018-4729-3","volume":"18","author":"A Girgis","year":"2018","unstructured":"Girgis, A., Durcinoska, I., Gerges, M., Kaadan, N., Arnold, A., Descallar, J., et al. (2018). Study protocol for a controlled trial of an eHealth system utilising patient reported outcome measures for personalised treatment and care: PROMPT-Care 20. BMC Cancer,18(1), 845. \nhttps:\/\/doi.org\/10.1186\/s12885-018-4729-3\n\n.","journal-title":"BMC Cancer"},{"issue":"1","key":"2304_CR60","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1023\/A:1008394107982","volume":"11","author":"MC Klee","year":"2000","unstructured":"Klee, M. C., King, M. T., Machin, D., & Hansen, H. H. (2000). A clinical model for quality of life assessment in cancer patients receiving chemotherapy. Annals of Oncology,11(1), 23\u201330.","journal-title":"Annals of Oncology"},{"issue":"5","key":"2304_CR61","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1001\/jama.2017.21903","volume":"319","author":"M Calvert","year":"2018","unstructured":"Calvert, M., Kyte, D., Mercieca-Bebber, R., Slade, A., Chan, A. W., King, M. T., et al. (2018). Guidelines for inclusion of patient-reported outcomes in clinical trial Protocols: The SPIRIT-PRO extension. The Journal of the American Medical Association,319(5), 483\u2013494. \nhttps:\/\/doi.org\/10.1001\/jama.2017.21903\n\n.","journal-title":"The Journal of the American Medical Association"}],"container-title":["Quality of Life Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11136-019-02304-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11136-019-02304-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11136-019-02304-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,21]],"date-time":"2020-09-21T23:33:42Z","timestamp":1600731222000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11136-019-02304-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,23]]},"references-count":61,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["2304"],"URL":"https:\/\/doi.org\/10.1007\/s11136-019-02304-8","relation":{},"ISSN":["0962-9343","1573-2649"],"issn-type":[{"value":"0962-9343","type":"print"},{"value":"1573-2649","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,23]]},"assertion":[{"value":"11 September 2019","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2019","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was approved by the Danish Data Protection Agency, registered at ClinicalTrials.gov by number NCT02892383 and carried out in accordance with the Helsinki Declaration and Good Clinical Practice guidelines. Informed consent was obtained from all participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}